CA3205876A1 - Modulation du microbiome d'un hote par administration de charges utiles d'adn a etalement reduit a un minimum - Google Patents

Modulation du microbiome d'un hote par administration de charges utiles d'adn a etalement reduit a un minimum

Info

Publication number
CA3205876A1
CA3205876A1 CA3205876A CA3205876A CA3205876A1 CA 3205876 A1 CA3205876 A1 CA 3205876A1 CA 3205876 A CA3205876 A CA 3205876A CA 3205876 A CA3205876 A CA 3205876A CA 3205876 A1 CA3205876 A1 CA 3205876A1
Authority
CA
Canada
Prior art keywords
virus
nucleic acid
bacterial cell
syn
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3205876A
Other languages
English (en)
Inventor
Jesus Fernandez Rodriguez
Xavier DUPORTET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eligo Bioscience
Original Assignee
Eligo Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2020/088043 external-priority patent/WO2021136812A1/fr
Application filed by Eligo Bioscience filed Critical Eligo Bioscience
Priority claimed from PCT/EP2021/087774 external-priority patent/WO2022144381A1/fr
Publication of CA3205876A1 publication Critical patent/CA3205876A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10151—Methods of production or purification of viral material
    • C12N2795/10152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des acides nucléiques d'intérêt pour moduler le microbiome d'un hôte, des vecteurs codant pour lesdits acides nucléiques et des procédés de modulation in vivo du microbiome d'un sujet par administration dudit acide nucléique d'intérêt.
CA3205876A 2020-12-30 2021-12-29 Modulation du microbiome d'un hote par administration de charges utiles d'adn a etalement reduit a un minimum Pending CA3205876A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063132190P 2020-12-30 2020-12-30
US202063132090P 2020-12-30 2020-12-30
EPPCT/EP2020/088043 2020-12-30
US63/132,190 2020-12-30
PCT/EP2020/088043 WO2021136812A1 (fr) 2019-12-30 2020-12-30 Véhicules d'administration de bactéries pour l'administration in vivo d'une charge utile d'adn
US17/138,084 2020-12-30
US63/132,090 2020-12-30
US17/138,084 US20210196828A1 (en) 2019-12-30 2020-12-30 Bacterial delivery vehicles for in vivo delivery of a dna payload
US202163137989P 2021-01-15 2021-01-15
US63/137,989 2021-01-15
PCT/EP2021/087774 WO2022144381A1 (fr) 2020-12-30 2021-12-29 Modulation du microbiome d'un hôte par administration de charges utiles d'adn à étalement réduit à un minimum

Publications (1)

Publication Number Publication Date
CA3205876A1 true CA3205876A1 (fr) 2022-07-07

Family

ID=87424019

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3206312A Pending CA3206312A1 (fr) 2020-12-30 2021-12-29 Proteines de liaison au recepteur chimerique resistantes a la degradation proteolytique
CA3205876A Pending CA3205876A1 (fr) 2020-12-30 2021-12-29 Modulation du microbiome d'un hote par administration de charges utiles d'adn a etalement reduit a un minimum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3206312A Pending CA3206312A1 (fr) 2020-12-30 2021-12-29 Proteines de liaison au recepteur chimerique resistantes a la degradation proteolytique

Country Status (5)

Country Link
EP (2) EP4271808A1 (fr)
JP (2) JP2024501870A (fr)
KR (2) KR20230128506A (fr)
CA (2) CA3206312A1 (fr)
IL (2) IL304050A (fr)

Also Published As

Publication number Publication date
EP4271809A1 (fr) 2023-11-08
KR20230128506A (ko) 2023-09-05
JP2024501870A (ja) 2024-01-16
JP2024501871A (ja) 2024-01-16
IL304020A (en) 2023-08-01
EP4271808A1 (fr) 2023-11-08
CA3206312A1 (fr) 2022-07-07
IL304050A (en) 2023-08-01
KR20230127265A (ko) 2023-08-31

Similar Documents

Publication Publication Date Title
US11534467B2 (en) Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
US11746352B2 (en) Microbiome modulation of a host by delivery of DNA payloads with minimized spread
EP4374923A2 (fr) Protéines de liaison à un récepteur chimérique pour utilisation dans des véhicules d'administration bactérienne
CA3120160A1 (fr) Proteines chimeres de liaison au recepteur destinees a etre utilisees dans des vecteurs pour delivrer des bacteries
CA3164131A1 (fr) Vehicules d'administration de bacteries pour l'administration in vivo d'une charge utile d'adn
US20210196828A1 (en) Bacterial delivery vehicles for in vivo delivery of a dna payload
US20230235361A1 (en) Method of containment of nucleic acid vectors introduced in a microbiome population
US11584781B2 (en) Chimeric receptor binding proteins resistant to proteolytic degradation
US20220064223A1 (en) Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles
US20240102026A1 (en) Microbiome modulation of a host by delivery of dna payloads with minimized spread
CA3205876A1 (fr) Modulation du microbiome d'un hote par administration de charges utiles d'adn a etalement reduit a un minimum
WO2022144381A1 (fr) Modulation du microbiome d'un hôte par administration de charges utiles d'adn à étalement réduit à un minimum
US20230134572A1 (en) Chimeric receptor binding proteins resistant to proteolytic degradation
CN116940677A (zh) 通过以最小传播递送dna有效载荷对宿主的微生物组调节